SAN FRANCISCO, CA -- (Marketwired) -- 06/11/14 -- Vista Partners announced today that it has updated coverage on Soligenix, Inc. (OTCBB: SNGX) and maintained its twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases.
Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.4B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis." Mr. Silver continues, "Soligenix also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($270M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis, a potentially billion dollar market." Mr. Silver continues, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $33 million in active government contract and grant funding still available to support its associated research programs through 2018." Mr. Silver concludes, "Company Insiders exercised options to purchase common shares in May 2014 according to Form 4's filed at sec.gov. Also, in the past two years Company Insiders have purchased or exercised options to purchase shares and no Company Insiders have sold shares during the same period."
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.